Mucosal immunization with lipopeptides derived from conserved regions of SARS-CoV-2 antigens induce robust cellular and cross-variant humoral immune responses in mice
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, has infected >600 million people in the ongoing global pandemic. Several variants of the SARS-CoV-2 have emerged in the last >2 years, challenging the continued efficacy of current COVID vacc...
Main Authors: | Raj S. Patel, Babita Agrawal |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-06-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1178523/full |
Similar Items
-
Progress and challenges in the clinical evaluation of immune responses to respiratory mucosal vaccines
by: Xuanxuan Zhang, et al.
Published: (2024-12-01) -
Humoral and cellular immunity to measles and rubella virus antigens in healthy subjects
by: M. A. Smerdova, et al.
Published: (2019-11-01) -
<italic toggle="yes">Lactobacillus</italic> Mucosal Vaccine Vectors: Immune Responses against Bacterial and Viral Antigens
by: Jonathan S. LeCureux, et al.
Published: (2018-06-01) -
Mucosal Vaccination with <i>Lactococcus lactis</i>-Secreting Surface Immunological Protein Induces Humoral and Cellular Immune Protection against Group B <i>Streptococcus</i> in a Murine Model
by: Diego A. Diaz-Dinamarca, et al.
Published: (2020-03-01) -
Mucosal immunity in Toxoplasma gondii infection
by: Schulthess J., et al.
Published: (2008-09-01)